Abbott Laboratories (ABT) reports robust earnings growth and margin expansion, driven by medical devices, despite headwinds ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Abbott forecasts an adjusted operating margin of approximately 23.5% of sales, down from prior guidance of 23.5%- 24.0%.

If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock ...

Abbott Laboratories ( NYSE: ABT) was upgraded to Buy from Hold at Jefferies following its Q2 results and revised guidance, as ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.4% year on year to $11.14 billion. Its non-GAAP profit of $1.

The S&P 500 Index ($SPX) (SPY) today down -0.08%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.44%, and the ...

Investors who hold lithium mining firms like Albemarle (ALB) and Lithium Americas (LAC) will enjoy Thursday’s rally. ALB stock gained 7.57% while LAC stock closed at 8.82%. A Chinese miner, Zangge ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Friday closed down -0.01%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.32%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.05%. September E-mini S&P futures (ESU25) fell -0.08% ...

Abbott Labs reported a mixed bag of Q2 2025 earnings, showing impressive growth in some areas and facing headwinds in others. Sales grew by almost 7%, and adjusted EPS saw an 11% increase. Medical ...

Governor Greg Abbott joined Chief of the National Guard Bureau and member of the Joint Chiefs of Staff General Steven ...